oncolytic herpes simplex virus (oHSV)-rQT3 for cholesteatoma treatment

  2. Projects
  3. oncolytic herpes simplex virus (oHSV)-rQT3 for cholesteatoma treatment
  4. Brief
This Project is based on the following Technology:
Tags: cancer biopharma features immunotherapy amphiphilic
Short Description:

Develop 
oHSV with armed gene TIMP3 as a novel cholesteatoma therapy.

Long Description:

Cholesteatomas (CHSTs) are invasive growths of keratinizing squamous epithelium in the middle ear and mastoid that cause deafness, dizziness, facial nerve paralysis, brain abscess, meningitis, and death. Currently, CHST is treated only by a costly surgery associated with complications and 15-70% recurrence rates. CHST pathogenesis is associated with high levels of matrix metalloproteinases (MMPs). The human TIMP3 inhibits all MMPs activity. Therefore, it is possible that the inhibition of MMPs by TIMP3 could prevent CHSTs’ progression.

We aim to develop 
oHSV (rQT3) that expresses human tissue inhibitor of metalloproteinases 3 (TIMP3), as a novel non-surgical product for CHST therapy. The preliminary data showed oHSV (rQT3) has enhanced cytotoxic effect against CHST cells.


Potential Applications:
Potential applications not yet defined for this project

Recent Activity in this Project